Tilray Inc. (TLRY)

30.23
0.93 3.20
NASDAQ : Health Technology
Prev Close 29.30
Open 29.68
Day Low/High 29.58 / 30.69
52 Wk Low/High 28.72 / 300.00
Volume 533.41K
Avg Volume 1.54M
Exchange NASDAQ
Shares Outstanding 80.98M
Market Cap 3.06B
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)
Tilray Signs First Deal to Sell Cannabis to Germany From Portugal Facility

Tilray Signs First Deal to Sell Cannabis to Germany From Portugal Facility

Tilray signs a $3.3 million initial supply agreement with a medical cannabis company in Germany.

Tilray® Announces Agreement To Export First Shipment Of Medical Cannabis From Portugal To Germany

Tilray® Announces Agreement To Export First Shipment Of Medical Cannabis From Portugal To Germany

Tilray, Inc. (NASDAQ:TLRY), a global pioneer in cannabis research, cultivation, production and distribution, today announced it has entered into an agreement with Cannamedical Pharma GmbH ("Cannamedical") through its wholly-owned subsidiary Tilray...

These 3 Stocks May Be Near Bottom, and One May Get a 'Lyft'

These 3 Stocks May Be Near Bottom, and One May Get a 'Lyft'

It's tough to find when a stock has hit the floor, so let's look at three that fell on earnings and could be poised to rise.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BCRH, DGSE Downgrades: ARLP, CIT, CSLT, ERIC, FTI, LE, NTZ, PICO Initiations: AFIN, BRY, BV, CCB, MYFW, SAGE, TLRY, XERS Read on to get TheStreet Quant Ratings' detailed report:

Cannabis Corner: Canopy Growth Miss Weighs on Pot Sector

Cannabis Corner: Canopy Growth Miss Weighs on Pot Sector

Canopy Growth reports a quarterly loss of C$1.28 billion.

Are New Lows in Store for Canopy Growth on Earnings Miss?

Are New Lows in Store for Canopy Growth on Earnings Miss?

Canopy Growth could be heading for new lows if longtime support falters. Here's where it's at.

Dow Closes Down 800 Points as Yield-Curve Inversion Sparks Recession Fear

Dow Closes Down 800 Points as Yield-Curve Inversion Sparks Recession Fear

Stocks finished sharply down Wednesday as weak economic data from China, GDP contraction in Germany, and the first inverted U.S. yield curve in more than 12 years stoked fears of a global recession.

Cannabis Corner: Pot Stocks Rocked as Tilray Gets Hammered

Cannabis Corner: Pot Stocks Rocked as Tilray Gets Hammered

Tilray sinks and the entire cannabis sector tumbles.

Tilray Gets Buried After Wider Loss but Piper Jaffray Remains Bullish Long-Term

Tilray Gets Buried After Wider Loss but Piper Jaffray Remains Bullish Long-Term

Analysts at Piper Jaffray believe that while Tilray will face some near-term headwinds it is still well-positioned to be the big winner in the cannabis space.

3 Big Stories to Watch: China's Economic Data, Tilray Earnings, CBS-Viacom Deal

3 Big Stories to Watch: China's Economic Data, Tilray Earnings, CBS-Viacom Deal

It's Wednesday, August 14, here's three big stories investors should be watching.

Cisco, Tariffs Delay, Weak China Data, ViacomCBS, Apple - 5 Things You Must Know

Cisco, Tariffs Delay, Weak China Data, ViacomCBS, Apple - 5 Things You Must Know

U.S. stock futures decline a day after the U.S. said it would hold off on levying tariffs on Chinese imports, including consumer products such as cellphones, laptops and toys; Cisco and Macy's report earnings; CBS and Viacom merge to form a $30 billion media giant; Tilray sinks after posting a wider-than-expected quarterly loss.

Replay: Jim Cramer's Breaking Down Tariffs, and the U.S.-China Trade War

Replay: Jim Cramer's Breaking Down Tariffs, and the U.S.-China Trade War

Jim Cramer's tackling the U.S.-China trade war and his thoughts on the tariffs being pushed back to December 15.

Tilray Drops on Wider Than Expected Loss

Tilray Drops on Wider Than Expected Loss

The Canadian cannabis company beat analysts' revenue expectation. Net selling price dropped.

Tilray, Inc. Reports Second Quarter 2019 Financial Results

Tilray, Inc. Reports Second Quarter 2019 Financial Results

Tilray, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY), a global pioneer in cannabis research, cultivation, production and distribution, today reported financial results for the second quarter ended June 30, 2019.

Tilray's Not Necessarily the Cream of the Crop

Tilray's Not Necessarily the Cream of the Crop

A host of other cannabis-related stocks has sprouted up that appear better for investing.

Earnings to Tell Whether Cannabis' High Growth Story Is Going to Pot

Earnings to Tell Whether Cannabis' High Growth Story Is Going to Pot

After a 2018 high, marijuana stocks are gaining popularity again, but which ones are producing the most green for investors? Here are the charts.

Jim Cramer Says Cannabis Is Getting Hot Again

Jim Cramer Says Cannabis Is Getting Hot Again

Jim Cramer weighs in on Tilray and why he's looking at other cannabis stocks.

It's Tough to Weed Through the Data on Tilray

It's Tough to Weed Through the Data on Tilray

The largest impediment to success for firms like TLRY -- which is expected to report a 27 cent loss per share Tuesday night -- remains federal legalization of marijuana across the U.S.

Tilray Stock Gains Ahead of Highly Anticipated Earnings Release

Tilray Stock Gains Ahead of Highly Anticipated Earnings Release

Tilray will look to sustain a sanguine sentiment on cannabis stocks on Tuesday.

All That Glitters Is Cramer: Jim Cramer Tackles Gold, Cannabis and the Markets

All That Glitters Is Cramer: Jim Cramer Tackles Gold, Cannabis and the Markets

Jim Cramer tackles when investors should be getting into gold, whether or not now is the time to sell and what he thinks of the cannabis industry.

Tilray Could Be Poised to Move Higher

Tilray Could Be Poised to Move Higher

There has been some recent consolidation and accumulation in the cannabis stock that could be setting the stage for an upside move.

Fear Not the Curve, Sizing Up Earnings and Ways to Play Amgen: Market Recon

Fear Not the Curve, Sizing Up Earnings and Ways to Play Amgen: Market Recon

Understanding yourself and the investing environment you are in are keys to avoiding panic brought on by fear.

Hong Kong Protests, Gold, T-Mobile, Verizon, Tilray - 5 Things You Must Know

Hong Kong Protests, Gold, T-Mobile, Verizon, Tilray - 5 Things You Must Know

U.S. stock futures fall as unrest in Hong Kong and the ongoing trade tensions between the U.S and China make for jittery investors; Oregon is the 16th state to join a lawsuit blocking the merger of T-Mobile US and Sprint; Verizon reaches deal to sell blogging website Tumblr.

Tilray® Imports GMP-Certified CBD Into The U.S. For Two Clinical Trials Led By NYU School Of Medicine

Tilray® Imports GMP-Certified CBD Into The U.S. For Two Clinical Trials Led By NYU School Of Medicine

Tilray, Inc. (NASDAQ:TLRY), a global pioneer in cannabis research, cultivation, production, and distribution, today announced it has received approval from the U.

(Photo: Business Wire)

(Photo: Business Wire)

Tilray, Inc. ("Tilray" or "the Company") (NASDAQ:TLRY), a global pioneer in cannabis research, cultivation, production and distribution, today announced that its wholly-owned subsidiary Tilray Portugal Unipessoal Lda.

Aurora Cannabis Gains 10% and Takes Sector Higher After Issuing Solid Guidance

Aurora Cannabis Gains 10% and Takes Sector Higher After Issuing Solid Guidance

ACB stock rallied after the firm says it expects to generate C$100 million to C$107 million in revenue for the three months ended June 30.

Cannabis Company Sundial Growers Wilts in Public Debut

Cannabis Company Sundial Growers Wilts in Public Debut

The shares slumped amid concern about another Canadian cannabis company's regulatory issues.

Jim Cramer: Will Beyond Meat Become the Next Fitbit or GoPro?

Jim Cramer: Will Beyond Meat Become the Next Fitbit or GoPro?

Jim Cramer's keeping a close eye on Beyond Meat.

When You Should Consider Buying Beyond Meat, According to Jim Cramer

When You Should Consider Buying Beyond Meat, According to Jim Cramer

Let's talk Beyond Meat.

Beyond Meat Chewed Up as Secondary Offering Takes Bite Out of Bullishness

Beyond Meat Chewed Up as Secondary Offering Takes Bite Out of Bullishness

The secondary offering of the producer of plant-based meat substitutes is priced well below its Wednesday's close.

TheStreet Quant Rating: D- (Sell)